Is retatrutide an approved medicine?

No. Retatrutide is investigational and has not been approved by any regulator. We supply it as a research chemical for laboratory use only.

What has retatrutide research looked at?

Receptor pharmacology in cells and animals, early human safety and pharmacokinetics, and phase-2 trials in obesity, type-2 diabetes and fatty-liver disease that measured weight, glucose and liver-fat markers. The cited studies are listed above.

A single peptide that activates the GIP, GLP-1 and glucagon receptors, described in the literature as a triple agonist.

Retatrutide research: what the studies have looked at

This page collects the published research on retatrutide (LY3437943), for reference. For each study it says what was investigated and in what model or trial phase, not a result to expect, and none of it is medical advice. Retatrutide is an investigational compound; what we supply under this name is a research chemical for laboratory use only.

What retatrutide is

Retatrutide is a single peptide engineered to switch on three receptors at once, those for GIP, GLP-1 and glucagon, which is why the literature calls it a triple agonist. It has not been approved by any medicines regulator anywhere. It is still in clinical development, so every human figure below comes from a trial run under supervision, not from routine use. The material we supply with this identity is unapproved research material, not a licensed medicine, and it is not for human or animal use.

What the studies investigated

Coskun et al. (2022), Cell Metabolism 34(9):1234-1247. In vitro, rodent and phase-1. Characterised the receptor pharmacology of retatrutide across the three targets and reported early human pharmacokinetics Source.

Urva et al. (2022), The Lancet 400(10366):1869-1881. Human, phase-1b, type-2 diabetes. Investigated safety, tolerability and pharmacokinetics of ascending once-weekly doses Source.

Jastreboff et al. (2023), New England Journal of Medicine 389(6):514-526. Human, phase-2, obesity. Investigated body-weight change over 48 weeks against placebo Source.

Rosenstock et al. (2023), The Lancet 402(10401):529-544. Human, phase-2, type-2 diabetes. Investigated change in HbA1c and body weight against placebo Source.

Sanyal et al. (2024), Nature Medicine 30(7):2037-2048. Human, phase-2a, MASLD. Investigated change in liver-fat content over 24 weeks Source.

Mechanism, as described in the literature

The three receptors it targets sit on different tissues, and the papers describe the rationale as combining the appetite and glucose effects linked to GIP and GLP-1 with the energy-expenditure effects attributed to glucagon signalling. Whether that becomes a durable advantage over existing single or dual agonists is exactly what the ongoing phase-3 programme is built to answer. The trials so far measured body weight, HbA1c, liver fat and safety over fixed windows, not long-term clinical outcomes.

The material we supply

We supply retatrutide as a research chemical, released against a written specification with a batch certificate of analysis. It is not a medicine and is not for human or animal use. For the vial sizes, the price per mg and how to order, see where to buy retatrutide wholesale; the COA lookup pulls the certificate for any batch. The references above link to each study’s journal or DOI record; this summary is for research and educational reference only.